Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Exclcirc (Suzhou) Biomedical Co. Ltd. has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is handled by 1 distinct examiner in 1 distinct art unit. This singular focus suggests a targeted approach to patenting within the biotechnology sector. Having only a single pending office action means the company's current prosecution resources are not divided across multiple fronts.
PERSONS, JENNA L is the busiest examiner for this portfolio with the pending office action. Because prosecution is limited to a single examiner and a single art unit, the strategy is highly dependent on the individual examiner's interpretation of the case. This streamlined prosecution environment allows for a direct engagement with PERSONS, JENNA L. The concentration in the art unit further simplifies the regulatory landscape for this specific biomedical portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PERSONS, JENNA L | 1 | 50.8% | +61.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18475347 | CIRCULAR RNAS FOR EXPRESSING URATE OXIDASE, AND PREPARATION METHODS AND USES THEREOF | PERSONS, JENNA L | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18475347 | CIRCULAR RNAS FOR EXPRESSING URATE OXIDASE, AND PREPARATION METHODS AND USES THEREOF | PERSONS, JENNA L | 1656 | §103§112DP | Non-Final OA | — | Pending | Sep 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialExclcirc (Suzhou) Biomedical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jenna L Persons has the most, with 1 of Exclcirc (Suzhou) Biomedical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
